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Background/Aims
Refractory gastroesophageal reflux disease (GERD) is very common, affecting up to 40% of the patients receiving proton pump 
inhibitor (PPI) therapy. However, there is not much information about the clinical characteristics of these patients. The aim of 
the study is to compare the clinical characteristics of PPI responders vs non-responders.
Methods
Consecutive GERD patients receiving PPI once or twice daily were evaluated by a questionnaire and a personal interview re-
garding their demographics, habits, clinical characteristics and endoscopic findings. The patients were divided into 3 groups: 
Patients who fully responded to PPI once daily (Group A, n = 111), patients who failed PPI once daily (Group B, n = 78) 
and patients who failed PPI twice daily (Group C, n = 56). 
Results
A total of 245 patients (59.3% females, 52 ± 17.2 years of age) were included in this study. Cross-group differences (A vs 
B vs C) were detected for hiatal hernia (33% vs 51% vs 52%, P = 0.011); erosive esophagitis (19% vs 51% vs 30%, P ＜ 
0.0001); cough (24% vs 44% vs 43%, P = 0.007); sleep disturbances (19% vs 30% vs 38%, P = 0.033); chest symptoms 
(21% vs 35% vs 41%, P = 0.010); Helicobacter pylori status (25% vs 33% vs 48%, P ＜  0.0001), disease duration (1.6 ± 
0.8 vs 1.9 ± 1.0 vs 2.0 ± 1.1 years, P = 0.007), performed lifestyle interventions (68.5% vs 46.7% vs 69.6%, P = 0.043) 
and compliance (84% vs 55% vs 46%, P ＜  0.0001).
Conclusions
PPI failure (either once or twice daily) appears to be significantly associated with atypical GERD symptoms, disease duration 
and severity, H. pylori status, obesity, performed lifestyle interventions and compliance as compared with PPI responders.
(J Neurogastroenterol Motil 2011;17:387-394)
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Introduction
Gastroesophageal reflux disease (GERD) is a chronic and 
common medical problem. Population-based studies have dem-
onstrated that 44% of the US adult population reports GERD- 
related symptoms (heartburn and acid regurgitation) at least once 
a month and 20% once a week.
1-3 In addition, GERD has a sig-
nificant impact on health-care utilization and patients’ quality of 
life.
4,5
Currently, proton pump inhibitors (PPIs) represent the cor-
nerstone of GERD treatment. PPIs have been shown to have a 
profound inhibitory effect on gastric acid secretion resulting in 
high rates of esophageal mucosal healing and rapid control of 
GERD related symptoms.
6-8 However, in recent years, reports of 
PPI failure in GERD patients have accumulated and it is esti-
mated that about 10% to 40% of GERD patients remain sympto-
matic on standard-dose PPI.
9-11 
In the face of PPI failure, physicians often double the PPI 
dose, assuming that a higher PPI dose will eventually result in 
symptom resolution. However, this therapeutic strategy fre-
quently results in a less than satisfactory symptomatic response 
and the majority of patients continues to experience GERD 
symptoms despite increased doses of PPI.
12 As a result, research 
is now focused on exploring the underlying mechanisms that ac-
count for PPI failure.
Several mechanisms have been proposed to account for 
symptom generation in patients who failed to respond to PPI 
treatment, which include: weekly acidic reflux, duodeno-gastro-
esophageal reflux, and esophageal hypersensitivity.
13 In addition, 
compliance and adherence to treatment are also considered as an 
important cause of PPI failure, although none of the studies thus 
far compared compliance rates between PPI failures and PPI 
responder patients. In this study, we aimed to compare the clin-
ical characteristics of GERD patients who continued to be symp-
tomatic (PPI failure) on once or twice daily PPI with those who 
were successfully treated with once-daily PPI (PPI success) 
while on treatment.
Materials and Methods
Setting and Patients
Consecutive GERD patients receiving PPI (omeprazole 20 
mg, Dexxon, Israel) once or twice daily for at least 3 months were 
invited to participate in this study. Prior to PPI treatment, pa-
tients reported at least 3 episodes of heartburn per week.
All patients were evaluated by a questionnaire and a personal 
interview regarding their demographics, habits, compliance with 
treatment (if patients were taking the PPI daily), adherence to 
treatment (if patients took the PPI before a meal), clinical charac-
teristics and endoscopic findings. All patients were followed by a 
specifically designed heartburn clinic at the Rabin Medical 
Center, Israel.
Patients were divided into 3 groups: patients who fully re-
sponded to PPI once daily (group A), patients who failed PPI 
once daily (group B) and patients who failed PPI twice daily 
(group C).
The PPI success group (group A) included patients with a 
history of classic symptoms of GERD (heartburn and acid regur-
gitation) who reported complete symptom resolution on PPI 
once a day for the last 3 months.
The PPI failure groups were defined as patients who con-
tinued to report classic GERD symptoms (heartburn and acid re-
gurgitation) while on PPI once daily (group B) or twice daily 
(group C), at least 3 times a week for the last 3 months. Patients 
with atypical or extraesophageal manifestations of GERD were 
included in this study, as long as they complained of classic symp-
toms of GERD (heartburn and acid regurgitation) at the same 
time. Compliance and adherence to treatment were established 
during a personal interview and later were matched with in-
formation from patients’ electronic files.
Patients were excluded if they had history of gastric or esoph-
ageal surgery, were unable to sign an informed consent or unable 
to provide the information requested by the protocol. This study 
was approved by the Human Subjects Committee of the Rabin 
Medical Center.
Procedure
Patients meeting inclusion criteria were asked to provide a 
written informed consent before enrollment into the study. 
Subsequently, patients filled out a detailed questionnaire about 
demographics, lifestyle modifications related to GERD, com-
pliance and adherence to treatment. Patients were queried about 
disease duration, the presence of additional extraesophageal man-
ifestations of GERD and about symptoms suggestive of gastro-
paresis using the validated Gastroparesis Cardinal Symptom 
Index (GCSI) questionnaire. A validated process of translation of 
the GCSI into Hebrew was performed prior to its use in this 
study.PPI Failure
389 Vol. 17, No. 4   October, 2011 (387-394)
Demographic Questionnaire
All patients completed a questionnaire regarding age, gender, 
ethnicity, level of education, occupation and marital status. 
Information about current smoking and alcohol-drinking habits 
was also collected. Body mass index (BMI) was calculated using 
the individual’s weight and height. Patients were asked about co-
morbidities and other prescribed medications. All patients were 
asked about status of Helicobacter pylori, whether the infection was 
ever diagnosed and if eradication was successful (confirmed by a 
breath test). 
Assessment of Atypical Gastroesophageal Re-
flux Disease Symptoms
Patients were asked if they experienced atypical GERD 
symptoms, such as chest pain, cough, sleep disturbances, hoarse-
ness, abdominal pain and bloating, difficulty in swallowing and 
asthma.
Assessment of Lifestyle Modifications, Adher-
ence and Compliance
Patients were asked if they avoid late-night meals, if they cor-
rected a recent weight gain (if a weight gain was identified in the 
prior 3-month visit) and if they avoided a daily consumption of 
carbonated beverages.
Compliance was assessed during a personal interview by ask-
ing the patients if they kept taking the PPI at the prescribed dose 
during the last 3 months. Adherence was assessed by asking the 
patients if they took the PPI on an empty stomach, half an hour 
before a meal. Patients who took the PPI with or after a meal, and 
those who did not take PPI once a day (stop taking or take as 
needed) were considered non-adherent and/or non-compliant, 
respectively.
Endoscopic Data
Patients’ electronic files were evaluated for upper endoscopic 
findings in order to document the presence or absence of esoph-
ageal mucosal injury and hiatal hernia.
Assessment of Symptoms Suggestive of Gas-
troparesis
All patients were asked to complete and to rate symptoms 
suggestive of gastroparesis. For this purpose we used a translated 
and validated version of the GCSI. The GCSI consists of 3 sub-
scales of the patient assessment of upper gastrointestinal symp-
tom severity index (PAGI-SYM), selected to measure important 
symptoms related to gastroparesis, including nausea/vomiting, 
post-prandial fullness/early satiety and bloating.
14 The nausea/ 
vomiting subscale is comprised of 3 items: nausea, retching and 
vomiting. The post-prandial fullness/early satiety subscale is 
comprised of four items: stomach fullness, inability to finish a 
normal-sized meal, feeling excessively full after meals and loss of 
appetite. The bloating subscale is comprised of 2 items: bloating 
and stomach or belly visibly larger. Overall the GCSI includes 9 
questions and each question is rated by the responder according 
to its severity from 0 to 5 (0 = no symptoms to 5 = severe symp-
toms).The total score of GCSI was categorized as “severe” 
(GCSI ＞ 27) or “mild” (GCSI ≤ 27).
Statistical Methods
Data analysis was carried out using SPSS 11.0 statistical 
analysis software (SPSS Inc, Chicago, IL, USA). For con-
tinuous variables, such as age and duration of illness, descriptive 
statistics were calculated and reported as mean ± SD as well as 
median (min-max) as appropriate. Normality of distribution of 
continuous variables was assessed using the Kolmogorov-Smir-
nov test (cut off at P = 0.010). Categorical variables such as sex 
and the presence of co-morbidities were described using fre-
quency distributions and were presented as frequency (%). 
Depending on the distribution, continuous variables were com-
pared across groups using one way analysis of variance (ANOVA) 
or the Kruskal Wallis test. Pair wise, post hoc comparisons for 
significance across differences were assessed by Bonferroni’s test 
or the Mann-Whitney U. Categorical variables were compared 
across groups using the chi square test (exact as necessary). Mul-
tinomial logistic regression was used to model group member-
ship. Odds ratios were estimated with 95% confidence intervals. 
All tests were 2-sided and considered significant at P ＜ 0.05.
Results
Demographics
A total of 245 subjects were included in this study: 111 pa-
tients who fully responded to PPI once daily (group A), 78 pa-
tients who failed PPI once daily (group B) and 56 patients who 
failed PPI twice daily (group C).
Subjects’ mean age was 52.3 ± 17.2 and 59.3% of the pa-
tients were female, with no significant across group differences. 
Patients’ characteristics are presented by group in Table 1. No Ram Dickman, et al
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Table 1. Subject’s Characteristics by Treatment Group 
Group A (n = 111) Group B (n = 78) Group C (n = 56) P-value
a
Age (yr)   51.4 ± 17.4   53.9 ± 16.03   51.6 ± 18.5 0.581
Sex (% females)        63.1        56.4        57.1 0.620
Area of origin (%) 0.731
    Israel         64.0        55.1        53.6
    Eastern Europe         13.5        15.4        16.1
    Western Europe           5.4          7.7          3.6
    North Africa           3.6          6.4        12.5
    Asia         12.6        14.1        12.5
    Other           0.9          1.3          1.8
Weight (kg)
b   70.8 ± 14.2 74.05 ± 14.5   70.9 ± 13.5 0.271
Height (cm)
b 166.1 ± 9.5 165.3 ± 9.8 163.5 ± 22.1 0.844
BMI (kg/cm
2)
b   28.7 ± 4.5   27.2 ± 5.1   25.6 ± 4.1 0.061
Obese (% with BMI ≥ 30 kg/cm
2)        12.7        32.1        12.5 0.001
Weight (kg)
b   70.8 ± 14.2 74.05 ± 14.5   70.9 ± 13.5 0.273
Family status (%)   0.533
    Single         21.6        16.7        25.0
    Married         64.0        64.1        55.4
    Divorced           4.5        11.5          8.9
    Widowed           9.9          7.7        10.7
Number of children
b   1.99 ± 1.6     2.4 ± 1.5     2.4 ± 1.9 0.081
Present smokers (%)        15.3          5.1        12.5 0.070
Non-alcohol drinkers (%)        80.2        87.7        92.7 0.080
At least one family member with GERD (%)        37.2        43.6        39.3 0.722
Present smokers (%)        15.3          5.1        12.5 0.070
Group A, patients who fully responded to proton pump inhibitor (PPI) once daily; Group B, patients who failed PPI once daily; Group C, patients who failed PPI twice
daily; BMI, body mass index; GERD, gastroesophageal reflux disease.
aP-value is for across-group comparison (post hoc testing was conducted for significant findings), 
bMean ± SD.
difference was detected in BMI across patient groups, and when 
BMI was categorized to obese (BMI ≥ 30 kg/m
2) vs non-obese 
(BMI ＜ 30 kg/m
2), group B had a significantly greater pro-
portion of obese subjects compared to group A (P = 0.001) or 
group C (P = 0.006). However, group A and C was not sig-
nificantly different regarding obesity (P = 0.243). Present smok-
ing did not differ across groups (P = 0.070), with fewer smokers 
among group B. Alcohol consumption also did not differ across 
groups (P = 0.080), with a somewhat greater proportion of 
non-drinkers in group C.
Co-morbidities
Co-morbidities are presented by group in Table 2. H. pylori 
infection was significantly less frequently observed in group A 
than group C (P = 0.002) but not lower than group B (P = 
0.061). The difference between group B and C was also not sig-
nificant (P = 0.061). Diabetes differed significantly across 
groups. A significantly greater proportion of patients from group 
B compared with group A were diabetic (P = 0.010), though no 
difference was detected between groups A and C (P = 0.221) 
and the difference between group B and C was not significant (P 
= 0.070). In addition, hypoglycemic agents were prescribed sig-
nificantly more frequently to patients from group B than group A 
(P = 0.001) and marginally more frequently than for group C (P 
= 0.090). Prescription for these medications was not sig-
nificantly different between group A and C (P = 0.111). Hyper-
tension was significantly different across groups, with a sig-
nificantly smaller proportion of patients from group A having hy-
pertension than subjects in group B (P = 0.008) or C (P = 
0.042), but the two treatment failure groups (B and C) did not 
differ from one another in terms of this co-morbidity (P = 
0.133). Chronic liver disease also differed significantly across 
groups. A significantly smaller proportion of patients from group 
A had chronic liver disease than patients from group B (P = 
0.009). However, patients in group A were not different from pa-
tients in group C (P = 0.111) and patients from group B was not 
different from patients in group C regarding the prevalence of 
chronic liver disease (P = 0.023). Significantly fewer antihyper-PPI Failure
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Table 2. Assessment of Co-morbidities, and Use of Medications 
by Group
Group A
(n = 111)
Group B
(n = 78)
Group C
(n = 56)
P-value
a
Co-morbidities (%)
    Hypertension  17.1 33.3 28.6 0.030
    Diabetes mellitus 9.0 21.8 12.5 0.043
    Chronic liver disease  0.9 9.0 5.4 0.031
    Ischemic heart disease  5.4 6.4 14.3 0.111
    Renal disease   0 2.6  0 0.123
    Depression  6.3 7.7 3.6 0.611
    Hypothyroidism  4.4 10.3 8.9 0.281
    Irritable bowel syndrome  3.6 6.4 3.6 0.610
    Inflammatory 0 1.3 1.8 0.410
      bowel disease 
    Asthma  8.1 7.7 14.3 0.362
    H. pylori infection 25.2 33.3 48.2 0.002
Medications (%)
    Aspirin  14.4 19.2 21.4 0.480
    Antihypertensives  15.3 25.6 17.9 0.210
    Antihyperglycemics   0.9 12.8 5.4 0.002
    Psychiatric medications  12.6 11.5 17.9 0.531
Group A, patients who fully responded to proton pump inhibitor (PPI) once 
daily; Group B, patients who failed PPI once daily; Group C, patients who failed
PPI twice daily; H. pylori, Helicobacter pylori.
aP-value is for across-group comparison (post hoc testing was conducted for 
significant findings).
Table 3. Assessment of Atypical Gastroesophageal Reflux Disease
Symptoms by Group
Group A
(n = 111)
Group B
(n = 78)
Group C
(n = 56)
P-value
a
Symptoms (%)
    Cough 24.3 43.6 42.9 0.008
    Hoarseness 22.5 25.6 30.4 0.540
    Difficulty in swallowing 23.4 30.8 35.7 0.221
    Sleep disturbances 18.9 29.5 37.5 0.033
    Chest pain 20.7 34.6 41.1 0.010
    Abdominal pain 31.5 39.7 50.0 0.065
    Bloating 23.4 26.9 30.4 0.620
Group A, patients who fully responded to proton pump inhibitor (PPI) once 
daily; Group B, patients who failed PPI once daily; Group C, patients who failed
PPI twice daily.
aP-value is for across-group comparison (post hoc testing was conducted for 
significant findings).
Table 4. Endoscopic Findings by Group 
Group A
(n = 111)
Group B
(n = 78)
Group C
(n = 56)
P-value
a
Diaphragmatic hernia (%) 33.3 51.3 51.8 0.017
Erosive Esophagitis (%)
    Any grade 18 51.3 30.4 ＜ 0.0001
    Los Angeles Grade A-B 95 92.5 76.5 0.001
    Los Angeles Grade C-D 5 7.5 23.5 0.001
Group A, patients who fully responded to proton pump inhibitor (PPI) once 
daily; Group B, patients who failed PPI once daily; Group C, patients who failed
PPI twice daily.
aP-value is for across-group comparison (post hoc testing was conducted for 
significant findings).
glycemic agents were prescribed to group A than group B (P = 
0.001), but no difference was noted between group A and group 
C (P = 0.110). The difference between group B and C was not 
significant (P = 0.092).
Atypical Gastroesophageal Reflux Disease Sym-
ptoms
Atypical GERD symptoms are presented by group in Table 
3. A number of symptoms differed significantly across treatment 
groups. The proportion of subjects reporting cough differed sig-
nificantly across treatment groups, and was significantly less fre-
quently reported by patients in group A than those in group B (P 
= 0.004) or C (P = 0.007); however, there was no significant 
difference between group B and C (P = 0.144). Sleep dis-
turbances significantly differed across groups, driven by the sig-
nificantly lower prevalence among group A than group C (P = 
0.006). The prevalence of sleep disturbances was marginally low-
er in group A compared with group B (P = 0.065) and margin-
ally lower in group B compared with group C (P = 0.090). Chest 
pain was significantly less prevalent in group A than group B (P 
= 0.025) or group C (P = 0.003), but there was no significant 
difference between group B and C (P = 0.113).
Endoscopic Findings
Endoscopic findings are presented by group in Table 4. 
Hiatal hernia was significantly less prevalent in group A than ei-
ther group B (P = 0.011) or group C (P = 0.021). However, 
there was no difference in the prevalence of hiatal hernia between 
group B and C (P = 0.550). Erosive esophagitis was signifi-
cantly more prevalent in group B than either group A (P ＜ 
0.0001) or C (P = 0.008). Erosive esophagitis was significantly 
more frequent in group C than group A (P = 0.033). Signifi-
cantly less severe grading of erosive esophagitis (Los Angeles A 
and B) was noted in group C than B (P = 0.011) or A (P = 
0.001) but no difference between group A and B (P = 0.561) 
was noted. Significantly more severe grading of erosive esoph-
agitis (Los Angeles C and D) was noted in group C than B (P = Ram Dickman, et al
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Table 5. Multinomial Logistic Regression of Group Membership
OR 95% CI for OR P-value
a
Group A 
    Intercept 0.12
    Hernia 0.46 0.228-0.98 0.045
    Cough 0.36   0.16-0.78 0.01
    Implementation of lifestyle 0.79   0.35-1.78 0.571
      interventions
    Compliance with treatment 9.59   4.19-21.94 ＜ 0.001
    GCSI 0.94   0.91-0.98 0.003
    Obese (BMI ≥ 30 kg/cm
2) 1.18   0.40-3.47 0.766
Group B
    Intercept 0.069
    Hernia 0.97   0.45-2.06 0.926
    Cough 0.98   0.46-2.10 0.96
    Implementation of lifestyle 0.33   0.15-0.72 0.005
      interventions
    Compliance with treatment 1.69   0.79-3.65 0.174
    GCSI 0.97   0.94-1.01 0.126
    Obese (BMI ≥ 30 kg/cm
2) 3.82   1.45-10.09 0.007
Group A, patients who fully responded to proton pump inhibitor (PPI) once 
daily; Group B, patients who failed PPI once daily; Group C, patients who failed
PPI twice daily; GSCI, Gastroparesis Cardinal Symptom Index; BMI, body 
mass index.
ORs were estimated with 95% CIs. All tests are 2-sided and considered 
significant at P ＜ 0.05. 
aP-value is for across-group comparison (post hoc 
testing was conducted for significant findings).
0.010) or A (P = 0.001) but no difference between group A and 
B (P = 0.562) was noted (Table 4).
Lifestyle Modifications, Adherence and Com-
pliance With Treatment
Patients were asked if they avoid late-night meals, if they cor-
rected a recent weight gain, and if they avoid a daily consumption 
of carbonated beverages. Significant differences across group 
were also detected for lifestyle interventions (cross-group differ-
ences for A vs B vs C were 68.5% vs 46.7% vs 69.6%, re-
spectively [P = 0.042]), which were significantly less frequently 
implemented by group B than either group A (P = 0.007) or 
group C (P = 0.007). There was no significant difference in life-
style modification between group A and C (P = 0.511).
As previously mentioned, patients who took the PPI with or 
after a meal and those who did not take the prescribed PPI dose 
were considered non-adherent and/or non-compliant. Cross- 
group differences for group: A vs B vs C were 84% vs 55% vs 
46%, respectively (P ＜ 0.0001). Subjects in group A reported 
significantly higher adherence and compliance with treatment 
than subjects in group B (P ＜ 0.0001) or C (P ＜ 0.0001). 
Adherence and compliance were marginally lower in group C 
compared to group B (P = 0.084).
Symptoms Suggestive of Gastroparesis
Symptom severity score, as measured by the GCSI, differed 
significantly across groups and was significantly lower in group A 
than group B (P = 0.033) or group C (P = 0.001). The total 
GCSI score (mean ± SD) for group A vs B vs C was 11.05 ± 
9.22 vs 14.07 ± 8.50 vs 16.30 ± 10.40, respectively (P = 
0.002). However, the difference between group A and group B 
was not statistically significant (P = 0.170). The prevalence of 
symptoms that were classified as severe (score ≥ 27) differed 
significantly across groups. The prevalence of severe GCSI (ex-
pressed as percentages) for group: A vs B vs C was 6.3% vs 7.7% 
vs 19.0%, respectively (P = 0.023). Symptoms that were classi-
fied as severe were 2-fold more frequently present in group C 
than group A (P = 0.010) or group B (P = 0.042). However, 
the prevalence of symptoms that were classified as severe did not 
differ between group A and B (P = 0.223).
Multinomial Logistic Regression
Group membership was modeled using multinomial logistic 
regression. As can be seen in Table 5, hernia, cough and in-
creased GCSI significantly diminished the odds of being a res-
ponder, while compliance with treatment increased the odds of 
being a responder by more than 9-fold. Furthermore, im-
plementation of lifestyle modifications significantly reduced the 
odds of single treatment failure, whereas obesity more than tri-
pled the odds of belonging to this group.
Discussion
The present study provided a comprehensive assessment of 
the clinical characteristics of GERD patients who responded to 
PPI therapy compared to those who did not. We noted that 
non-responders to standard dose PPI (group B) were much dif-
ferent from the responders (group A) in several important clinical 
characteristics, such as: atypical GERD symptoms, disease dura-
tion and severity, obesity, H. pylori status and compliance during 
treatment.
Lack of response to PPI treatment was associated with poor-
er adherence and/or compliance with treatment. Responders to 
standard dose PPI (group A) reported significantly higher com-
pliance with treatment than either the single or double treatment 
failure groups. The finding of poor compliance during PPI treat-PPI Failure
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ment among GERD patients has been previously described in 
several studies. According to a large population-based survey on-
ly 55% of the GERD patients took their PPIs as prescribed, 
whereas 37% failed to follow their therapeutic regimen for more 
than two weeks.
15 In GERD, the main obstacle in achieving 
proper compliance is related to the fact that GERD is a symp-
tom-driven disease in which patients adhere to treatment in-
structions as long as they experience symptoms. Hungin et al
16 
found that the presence or absence of symptoms, the severity of 
symptoms, and personal preference about when to take treatment, 
played a role in patient’s adherence to the schedule of medication 
consumption. In a systematic review, Fass et al
10 reported addi-
tional factors that affect compliance and adherence to treatment 
instructions, such as knowledge about the treated disorder, desire 
for personal control, the prescribed drug (taste, consistency, etc), 
side effects, number of pills per day, concomitant therapies, age, 
personality, socioeconomic status and healthcare coverage.
Timing and frequency of dosing are pivotal for maximum ef-
ficacy of medications such as PPIs. The latter should be taken on 
an empty stomach, 30 minutes prior to a meal. In one study, the 
authors demonstrated a significantly better gastric pH control 
when omeprazole or lansoprazole were taken 15 minutes before 
breakfast versus without breakfast.
17 Gunaratnam et al
18 found 
that only half of the patients with persistent GERD symptoms on 
PPI were dosed optimally and of those who were dosed sub opti-
mally, 39% consumed their PPI at bedtime and 4% as needed. In 
a 2000 Gallup survey, consumption of antireflux medications pri-
or to going to bed was reported by 52% of the subjects.
15
In this study, we also found that lifestyle modifications were 
significantly less frequently implemented by GERD patients who 
report lack of response to standard dose PPI treatment (group B) 
than responders to standard dose PPI (group A). Thus, in light 
of these findings and consistent with findings in other studies, it 
seems prudent to recommend assessment of compliance and life-
style modifications, such as weight control and late-night meals, 
i n  a l l  G E R D  p a t i e n t s  w h o  r e p o r t  l a c k  o f  r e s p o n s e  t o  P P I  
treatment. This should be carried out prior to ordering any in-
vasive and costly evaluative tests. Unfortunately, a subset of pa-
tients may not disclose that they are poorly compliant during their 
clinic visit. Treating physicians should repeatedly emphasize the 
need to consume PPIs on an empty stomach and 30 minutes pri-
or to a meal.
Another important observation of our study was the differ-
ence in disease severity across groups as assessed by upper gastro-
intestinal (GI) endoscopy. We found that non-responders (either 
to once or twice daily PPI) had more esophageal erosions sig-
nificantly than responders. There are several explanations for this 
finding: (1) Hiatal hernia was more prevalent among the 
non-responders; (2) Non-compliance with treatment was much 
more frequently observed among non-responders; and (3) The 
prevalence of obesity (BMI ≥ 30 kg/m
2) was higher among 
non-responders. All the aforementioned, hiatal hernia, obesity 
and non-compliance may result in higher esophageal acid ex-
posure, and consequently the potential occurrence of esophageal 
erosions. Another potential explanation is the increase in preva-
lence of more severe grading of erosive esophagitis (Los Angeles 
C and D) among non-responders. This is because grade C and D 
are less responsive to antireflux treatment than grade A and B.
Interestingly, cough was significantly more prevalent among 
non-responders than responders. It is possible that non-res-
ponders may have a higher degree of proximal esophageal ex-
posure to weekly acidic reflux. A recent impedance-pH study in 
refractory GERD patients while on PPI therapy showed that up 
to 68% of remaining heartburn episodes were associated with 
weekly acidic reflux.
19 In this study, high proximal extent of the 
refluxate was the only important factor associated with perception 
of reflux events, suggesting an increased sensitivity to chemical 
stimulus of the proximal esophagus in this group of patients.
We found that past H. pylori infection was significantly less 
frequent in the responders. The explanation for this finding is 
that the eradication of H. pylori infection upregulates gastric acid 
secretion and consequently increases esophageal acid exposure. 
Holtmann et al
20 demonstrated that of all patients with erosive 
esophagitis who received 4 weeks of pantoprazole 40 mg daily, 
23.7% of the H. pylori-negative patients failed to heal their esoph-
agitis when compared with 13.4% of the H. pylori-positive pa-
tients.
Furthermore, in this study, symptoms suggestive of gastro-
paresis significantly diminished the odds of being a responder. 
The relationship between refractory GERD and the presence of 
gastroparesis is an area that has been scarcely studied. A recent 
study has demonstrated that botulinum toxin injection of the py-
lorus in gastroparetic GERD patients who failed to respond to 
PPI treatment significantly improved their symptoms, albeit for a 
short period of time.
21
In another study, Kudara et al
22 evaluated gastric emptying in 
15 patients with erosive esophagitis. Four of the patients who ex-
perienced persistent heartburn demonstrated significant delayed 
gastric emptying when compared with the other 11 patients who 
had symptomatic improvement.Ram Dickman, et al
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An important limitation of the present study is the extraction 
of endoscopic data from electronic files and not from prospective 
assessment. Documentation of upper endoscopy results is de-
tailed in our GI department, where all GI physicians use the same 
computer report system. In our study, compliance was assessed 
by patient’s report rather than by a more objective measure, such 
as pill count. It is likely that non-compliant patients were inclined 
to under-report their compliance. If this is the case, then 
non-compliance with PPI in the treatment failure groups might 
have been even higher.
 In conclusion, our study is the first to provide a compre-
hensive assessment of the clinical characteristics of GERD pa-
tients who failed PPI therapy. We demonstrated that PPI failure 
(either once or twice daily) appeared to be significantly associated 
with atypical GERD symptoms, disease duration and severity, H. 
pylori status, obesity, lifestyle modifications and compliance com-
pared with PPI responders. These findings provide an important 
clinical tool for treating physicians when managing patients with 
GERD, who are refractory to treatment.
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